ImmunityBio (IBRX) Profit After Tax (2014 - 2026)

ImmunityBio (IBRX) has 13 years of Profit After Tax data on file, last reported at -$632.8 million in Q1 2026.

• On a quarterly basis, Profit After Tax fell 388.01% year-over-year to -$632.8 million in Q1 2026; TTM through Mar 2026 was -$854.5 million, a 108.83% decrease from a year earlier, with the FY2025 full-year figure at -$351.4 million, up 15.05% from the prior year.
• Profit After Tax for Q1 2026 stood at -$632.8 million, down from -$61.9 million in the prior quarter.
• Over the last five years, Profit After Tax for IBRX reached as high as -$59.2 million in Q4 2024 and fell as low as -$632.8 million in Q1 2026.
• Historically, Profit After Tax has averaged -$141.1 million across 5 years, with a median of -$108.3 million in 2022.
• Across the five-year window, Profit After Tax soared 74.64% in 2024 and sank 388.01% in 2026, its largest moves.
• Year by year, Profit After Tax stood at -$108.3 million in 2022, then plunged by 115.45% to -$233.4 million in 2023, then surged by 74.64% to -$59.2 million in 2024, then decreased by 4.57% to -$61.9 million in 2025, then tumbled by 922.53% to -$632.8 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$632.8 million in Q1 2026, -$61.9 million in Q4 2025, and -$67.3 million in Q3 2025.